EUCTR2017-003415-19-ES进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010
Contera Pharma0 个研究点目标入组 81 人开始时间: 2018年8月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Is able to read, understand, and provide written, dated informed consent prior to Screening Visit. Participants will be deemed likely to comply with study protocol and communicate with study personnel about adverse events (AEs) and other clinically important information.
- •2. Is male or female, between 18 and 80 years of age at Screening Visit.
- •3. Is diagnosed with idiopathic PD that meets UK Parkinson’s Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria and requires treatment with and shows responsiveness to levodopa.
- •4. Has experienced dyskinesia over a period of at least 3 months prior to Screening Visit
- •5. Has stable peak-effect dyskinesia (as reported by the subjects); the dyskinesia should be moderately to completely disabling (MDS-UPDRS, Part IV, item 4.2, rating = 3).
- •6. Has more than one hour of ON” time with troublesome dyskinesia during daily waking hours on a 24-hour PD subject diary on each of 2 consecutive days just prior to Visit 2, Week 0 (Baseline Visit).
- •7. Is on a stable levodopa dosing regimen requiring at least 3 dose administrations but no more than 6 dose administrations per day with at least 2 to 3 hour intervals between 2 successive doses of levodopa for at least 30 days prior to Screening Visit, and is expected to continue this levodopa regimen with no changes for the duration of study participation.
- •8. Must be on a stable dosing regimen if taking other anti-parkinsonian medication(s) and is expected to continue this regimen with no changes for the duration of study participation.
- •9. Is willing and able to stop using amantadine and/or monoamine oxidase inhibitors (MAOi), where applicable, from at least 4 weeks prior to Visit 2, Week 0 (Baseline Visit) and for the duration of study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 41
排除标准
- •A potential subject will not be eligible for participation in this study if any of the following criteria are met:
- •PD-Specific Criteria:
- •1. Has undergone surgery for the treatment of PD (e.g., pallidotomy, deep brain stimulation, fetal tissue transplantation) or has undergone any other major brain surgery.
- •Criteria related to psychiatric and other neurological disorders:
- •2. Has current diagnosis of Substance Use (including alcohol) Disorder (Abuse or Dependence, as defined by DSM 5th Edition), with the exception of caffeine and nicotine dependence, at Screening Visit or within 12 months prior to Screening Visit.
- •3. Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses such as bipolar disorder or major depressive disorder, or generalized anxiety disorder that are clinically predominant to their PD or have been predominant to their PD at any time within 6 months prior to Screening Visit.
- •4. Has other psychiatric (not including hallucinations due to side effects of dopamine therapy), neurological or behavioral disorders that in the opinion of the investigator may interfere with the conduct or interpretation of the study, including dementia, or subject who is considered violent.
- •5. Has a significant risk for suicidal behavior in the opinion of the investigator during the course of their participation in the study or
- •At Screening Visit: the subject scores yes” on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to a 6-month period prior to Screening Visit; or
- •At Screening Visit: the subject has had one or more suicidal attempts with reference to a 2-year period prior to Screening Visit; or
- •At Baseline Visit: the subject scores yes” on items 4 or 5 in the Suicidal Ideation section of the C SSRS with reference to Screening Visit; or
- •6. Has current seizure disorders (other than febrile seizures in childhood) requiring treatment with anti convulsants.
- •7. Has known serious ongoing symptomatic cerebral disease or cerebrovascular disease or any acute brain trauma requiring treatment with anti-convulsant therapy within 5 years prior to Screening Visit.
- •8. Has history of exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic dyskinesia without peak dose dyskinesia.
- •Criteria related to other medical conditions:
- •9. Has current evidence of clinically significant hematological, autoimmune, endocrine, cardiovascular, peripheral vascular, renal or gastrointestinal disorder or other known condition (eg. porphyria, unstable diabetes mellitus) that would possibly interfere with the subject’s participation in the study and/or assessments.
- •10. Has any malignant disease or a history of neoplasms treated within the 5 years prior to the Screening Visit, other than carcinoma in situ of the cervix or basal cell carcinoma of the skin.
- •11. Has orthostatic or symptomatic hypotension: a decrease of > 20 mm Hg in SBP and/or > 10 mm Hg in DBP after at least 3 minutes standing compared to the previous supine BP in 2 separate measurements and/or history or current episode of repeated hypotensive or vasovagal syncope.
- •12. Has known history or current episode of:
- •History of stroke or transient ischemic attack within 2 years prior to screening
- •History of myocardial infarction, or New York Heart Association Functional Classification of Heart Failure Class 3 or 4 within 2 years prior to screening.
- •Any clinically significant ECG abnormalities, including any findings of abnormal ventricular con
研究者
相似试验
进行中（未招募）
1 期
A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndromeMedDRA version: 17.1 Level: HLGT Classification code 10039911 Term: Seizures (incl subtypes) System Organ Class: 10029205 - Nervous system disordersEUCTR2013-003771-35-GBltragenyx Pharmaceutical Inc36
进行中（未招募）
1 期
Safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (liver disease) from nonalcoholic steatohepatitis (NASH).Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)MedDRA version: 20.0Level: HLTClassification code 10019669Term: Hepatic fibrosis and cirrhosisSystem Organ Class: 100000004871MedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 100000004871EUCTR2019-003932-22-DEBristol-Myers Squibb International Corporation270
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.MedDRA version: 9.1Level: LLTClassification code 10034382Term: Perennial allergic rhinitisEUCTR2007-006562-15-EEGlaxoSmithKline Research & Development Ltd288
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic RhinitisVasomotor/Idiopathic RhinitisEUCTR2004-004744-43-NOGlaxoSmithKline Research & Development Ltd347
进行中（未招募）
1 期
Baricitinib in Patients with COVID-19 InfectioCOVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001517-21-DEEli Lilly and Company1,400